107238-27-7 Usage
Uses
Used in Pharmaceutical Industry:
3-Pyridinecarbonitrile,5,6-diamino-(9CI) is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity allow for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
3-Pyridinecarbonitrile,5,6-diamino-(9CI) is also utilized as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties enable the creation of effective compounds for agricultural use, contributing to crop protection and yield enhancement.
Used in Medicinal Chemistry Research:
Due to its unique structure, 3-Pyridinecarbonitrile,5,6-diamino-(9CI) serves as a valuable research tool in medicinal chemistry. It can be used to explore new chemical reactions and synthesize novel compounds with potential therapeutic properties.
Used in Organic Synthesis:
3-Pyridinecarbonitrile,5,6-diamino-(9CI) is employed as a versatile building block in organic synthesis. Its reactivity allows for the formation of various functional groups and the creation of complex organic molecules for a wide range of applications.
Check Digit Verification of cas no
The CAS Registry Mumber 107238-27-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,7,2,3 and 8 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 107238-27:
(8*1)+(7*0)+(6*7)+(5*2)+(4*3)+(3*8)+(2*2)+(1*7)=107
107 % 10 = 7
So 107238-27-7 is a valid CAS Registry Number.
107238-27-7Relevant articles and documents
COMPOSITIONS AND METHODS FOR INHIBITING CD73
-
, (2019/12/25)
Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
Novel non-benzimidazole chk2 kinase inhibitors
McClure, Kelly J.,Huang, Liming,Arienti, Kristen L.,Axe, Frank U.,Brunmark, Anders,Blevitt, Jon,Guy Breitenbucher
, p. 1924 - 1928 (2007/10/03)
In a recent paper, [Arienti, K. L.; Brunmark, A.; Axe, F. U.; McClure, K. M.; Lee, A.; Blevitt, J.; Neff, D. K.; Huang, L.; Crawford, S.; Chennagiri, R. P.; Karlsson, L.; Brietenbucher, J. G. J. Med. Chem. 2005, 48, 1873], we described the discovery of a class of benzimidazole chk2 kinase inhibitors, exemplified by compound 1, which had radio-protective effects in human T-cells subjected to ionizing radiation. Here, a series of non-benzimidazole analogs intended to define the scope of the SAR about this new series of inhibitor, and allow for refinement of the binding model of these compounds to the chk2 kinase is described.
